An analytical study of laboratory tests and clinical effectiveness for combination therapies using GnRH antagonist/antiandrogen and GnRH aonist/antiandrogen in prostate cancer patients.

An analytical study of laboratory tests and clinical effectiveness for combination therapies using GnRH antagonist/antiandrogen and GnRH aonist/antiandrogen in prostate cancer patients. - An analytical study of laboratory tests and clinical effectiveness for combination therapies using GnRH antagonist/antiandrogen and GnRH aonist/antiandrogen in prostate cancer patients.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013151

Enrollment

Registered

2014-02-13

Start date

2014-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Cancer

Interventions

Degarelix + bicalutamide LHRH agonist + bicalutamide

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Male patients with histologically proven prostate cancer (all stages)

Exclusion criteria

Exclusion criteria: Patient who were inappropriate for this study judged by medical doctor

Design outcomes

Primary

Measure	Time frame
The proportion of patients whose serum PSA at day 28 are 90% or less compared to those before administration	—

Countries

Japan

Contacts

Public ContactMotohide Uemura

Osaka University Graduate School of Medicine Department of Organ Specific Regulation (Urology)

uemura@uro.med.osaka-u.ac.jp81668793531

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026